BLI 1401

Drug Profile

BLI 1401

Alternative Names: BLEX-404; BLI-1401; BLI-1401-2

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator BioLite Inc
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Breast cancer; Myelodysplastic syndromes
  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 24 Oct 2016 BioLite plans a phase II trial for Myelodysplastic syndromes and Chronic myelomonocytic leukaemia (First-line therapy, Combination therapy) in USA (PO, Liquid) (NCT02944955)
  • 04 Oct 2016 Preclinical trials in Chronic lymphocytic leukaemia in Taiwan (PO) before October 2016
  • 29 Jul 2016 Clinical trials in Breast cancer in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top